SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML

被引：5

作者：

Sutherland, May S. K. ^{[1
]}

Walter, Roland B. ^{[2
]}

Jeffrey, Scott C. ^{[1
]}

Burke, Patrick J. ^{[1
]}

Yu, Changpu ^{[1
]}

Harrington, Kimberly H. ^{[2
]}

Stone, Ivan ^{[1
]}

Ryan, Maureen C. ^{[1
]}

Sussman, Django ^{[1
]}

Zeng, Weiping ^{[1
]}

Benjamin, Dennis R. ^{[1
]}

Bernstein, Irwin D. ^{[2
]}

Senter, Peter D. ^{[1
]}

Drachman, Jonathan G. ^{[1
]}

McEarchern, Julie A. ^{[1
]}

机构：

[1] Seattle Genet Inc, Res & Translat Med, Bothell, WA USA

[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.3589.3589

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3589

引用

页数：2

共 45 条

[41] Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels
Bashey, S.
Krathen, M.
Sutherland, K.
Sundram, U.
Lingala, B.
Horwitz, S.
Hoppe, R.
Pulitzer, M.
Advani, R.
Kim, Y.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 : S95 - S95
[42] HMA800067, a novel CD38-targeting antibody-drug conjugate (ADC), demonstrated superior anti-tumor activity to daratumumab in preclinical B-cell malignancies models
Xu, Yan
Liang, Junqing
Jiang, Shuwen
Yang, Haibin
Zhang, Hui
Mao, Fangfang
Zhu, Jiahuan
He, Jianlin
Yang, Na
Wang, Jian
Zhang, WeiHan
Ren, Yongxin
Su, Weiguo
CANCER RESEARCH, 2024, 84 (06)
[43] ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling preclinical activity in NSCLC, ovarian and uterine cancer models, with a favorable toxicology profile in non-human primates
Hernandez, A.
Urosev, D.
Wong, J.
Lawn, S.
Wu, K.
Fu, L.
Stahl, K.
Lasalle, M.
Alonzo, D. A.
Yang, L.
Sagoe-Wagner, A. P.
Degefie, L.
Kim, C.
Wu, A.
Chen, C. W.
Higgins, R.
Petersen, M.
Colombo, R.
Barnscher, S. D.
Rich, J. R.
EUROPEAN JOURNAL OF CANCER, 2024, 211 : S5 - S5
[44] A Phase I, First-in-Human Study Evaluating the Safety and Preliminary Antileukemia Activity of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Other CD123-Positive Hematologic Malignancies
Daver, Naval G.
Erba, Harry P.
Papadantonakis, Nikolaos
DeAngelo, Daniel J.
Wang, Eunice S.
Konopleva, Marina Y.
Sloss, Callum M.
Culm-Merdek, Kerry
Zweidler-McKay, Patrick A.
Kantarjian, Hagop M.
BLOOD, 2018, 132
[45] A Single Dose of a Novel Anti-Human CD117-Amanitin Antibody Drug Conjugate (ADC) Engineered for a Short Half-Life Provides Dual Conditioning and Anti-Leukemic Activity and Extends Survival Compared to Standard of Care in Multiple Preclinical Models of Acute Myeloid Leukemia (AML)
Lanieri, Leanne
Lamothe, Tahirih L.
Miske, Oliver
McDonough, Sean M.
Sarma, Ganapathy N.
Bhattarai, Prashant
Latimer, Kellie
Dushime, Junia
Jain, Nidhi
Palchaudhuri, Rahul
Knihtila, Ryan
Pearse, Bradley R.
Proctor, Jennifer L.
Boitano, Anthony E.
Cooke, Michael P.
Davis, John C., Jr.
BLOOD, 2020, 136

← 1 2 3 4 5 →